Biohaven

Biohaven Net Change in Cash

The Net Change in Cash of Biohaven (BHVN) as of Nov 3, 2026 is 130.24 M USD. In the previous year, Net Change in Cash was -149.58 M USD — a change of -187.07% (higher).

Net Change in Cash

130.24 MUSD

YoY

-187.07%

Last updated:

Net Change in Cash of Biohaven is 2025 130.24 M USD. Net Change in Cash of Biohaven was 2024 -149.58 M USD. It decreases by -187.07% higher compared to the previous year.

The Biohaven Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
132.78 M USD
Jan 1, 2019
53.48 M USD
Jan 1, 2020
73.59 M USD
Jan 1, 2021
-6.45 M USD
Jan 1, 2022
165.55 M USD
Jan 1, 2023
9.52 M USD
Jan 1, 2024
-149.58 M USD
Jan 1, 2025
130.24 M USD
The Biohaven Net Change in Cash history
YEARNet Change in CashYoY
130.24 MUSD-187.07%
-149.58 MUSD-1,671.86%
9.52 MUSD-94.25%
165.55 MUSD-2,667.02%
-6.45 MUSD-108.76%
73.59 MUSD+37.60%
53.48 MUSD-59.72%
132.78 MUSD+23.06%
107.90 MUSD+388.03%
22.11 MUSD-7,232.26%
-310,000.00USD-117.51%
1.77 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Net Change in Cash of Biohaven is 130.24 M USD in 2025.

Net Change in Cash of Biohaven changed from -149.58 M USD to 130.24 M USD, representing a -187.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Biohaven since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biohaven

All Key Metrics — Biohaven